In January 2016, the US FDA further granted the Breakthrough Therapy Designation to olaparib for treating patients with metastatic-castration-resistant prostate cancer carrying BRCA1/2 or ATM mutations (https://www.astrazeneca.com/media-center/press-releases/2016/Lynparza-Olaparib-granted-Breakthrough-Therapy-Designation-by-US-FDA-for-treatment-of-BRCA1-2-or-ATM-gene-mutated-metastatic-Castration-Resistant-Prostate-Cancer-28012016.html#). This evidence concerns the gene ATM and Familial prostate cancer.